First gene therapy for adults with hemophilia B sustains safety and efficacy

Phase three trial results for only approved gene therapy for rare bleeding disorder reinforces lower bleeding rates, improved outcomes

12:00 PM

Author | Beata Mostafavi

vial of blood over dish blue yellow
Jacob Dwyer, Justine Ross, Michigan Medicine

The first and only approved gene therapy for adults with bleeding disorder hemophilia B remained safe and effective two years after treatment, according to new data from a Michigan Medicine-led trial.

The findings, which appear in the New England Journal of Medicine, reinforce previous trial results showing that the treatment is safe, lowers bleeding rates, and allows patients to stop using other therapies to manage the condition.

The gene therapy studied, Hemgenix, also boosted the levels of factor IX (FIX) — the protein missing in hemophilia B that prevents blood from clotting properly to control bleeding. Most patients with the hereditary condition need lifelong, continuous treatment to replace the deficient clotting factor to prevent life-threatening bleeding episodes.

“This is a transformative treatment for patients with hemophilia B who typically require one to two intravenous infusions per week from birth through the rest of their life,” said trial lead scientist Steven Pipe, M.D., professor of pediatrics and pathology at the U-M Medical School and hematologist-oncologist at U-M Health C.S. Mott Children’s Hospital. “This new gene therapy gives hope to pediatric patients that they can one day have an option that eliminates reliance on regular IV infusions and allows them to enjoy a freer, less restricted lifestyle.”

The phase three clinical results stem from the pivotal Mott-led HOPE-B trial, a multicenter study conducted at 33 sites in the United States and Europe that includes data from 2018 to 2021. Researchers will continue to follow patients through 2026.

The safety and effectiveness of Hemgenix were evaluated in two studies of 57 adult men ages 18 to 75 with severe or moderately severe hemophilia B. Scientists established effectiveness based on consistent decreases in the participants’ bleeding rates.

The new findings support the U.S. Food and Drug Administration’s recent approval of Hemgenix for adult hemophilia B patients who are on a preventive treatment regimen or have had life-threatening hemorrhage or repeated, serious spontaneous bleeding episodes.

This new gene therapy gives hope to pediatric patients that they can one day have an option that eliminates reliance on regular IV infusions and allows them to enjoy a freer, less restricted lifestyle.” Steven Pipe, M.D.

Hemophilia B affects about one in 40,000 people and predominantly men. Symptoms can include excessive bleeding from cuts, an injury, surgery, or dental work. Prolonged bleeding episodes can lead to serious complications, such as uncontrolled bleeding that can harm joints, muscles or internal organs, including the brain.

Hemgenix is a one-time outpatient therapy given as a single dose by IV infusion. It consists of a viral vector – a tool designed to transport genetic material into cells – that carries the gene for the blood clotting protein missing in hemophilia patients. The gene is expressed in the liver to produce the protein to limit bleeding episodes.

The most common adverse reactions associated with Hemgenix included liver enzyme elevations, headache, mild infusion-related reactions and flu-like symptoms.

Patients should be monitored for adverse infusion reactions and liver enzyme elevations in their blood.

Disclosures: Pipe has served as a paid consultant to several companies developing gene therapies for hemophilia B, including CSL Behring and uniQure, which provided funding for this trial.

Study cited: “Gene therapy with etranacogene dezaparvovec for hemophilia B,” New England Journal of Medicine. DOI: 10.1056/NEJMoa2211644

Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories close up of sensor
Health Lab
Stent sensor can warn of blockages in the bile duct
Currently, medical providers monitor biliary stent blockages through blood tests, meaning the problem must be significant enough for the body to notice. A sensor within the stent could enable doctors to recognize that bacterial sludge is accumulating and intervene before the patient begins to fall ill.
Female Urologist
Health Lab
A urologist explains women’s most common urological concerns — and how to treat them
Women with urological issue may not know how common — and treatable — they are, which keeps many from seeking proper care. But help is available.
Microscope
Health Lab
Nerve damage reduced in prediabetic mice with diet, exercise
A low calorie diet and high intensity exercise can reduce nerve damage in prediabetic mice, according to a Michigan Medicine study.
.S. Mott Children's Hospital and Von Voigtlander Women's Hospital aerial view
News Release
U-M Health Von Voigtlander Women’s Hospital receives highest designation for Maternal Levels of Care
Von Voigtlander Women’s Hospital in Ann Arbor verified to have the ability to handle even the most complex maternal care cases
Well-Being at Michigan Medicine podcast - a part of the Michigan Medicine Podcast Network.
Well-Being at Michigan Medicine
Introducing: Well-Being at Michigan Medicine
Well-being and how it brings teams together is so important. Michigan Medicine’s Chief Well-Being Officer, Elizabeth Harry, M.D., is bringing this topic, and many others, to audio life.
three friends standing outside rogel cancer center building with big white ribbons
Health Lab
A lung cancer survivor shaping lung cancer advocacy
One woman's unexpected lung cancer diagnosis leads her to help many who aren't aware they're at risk of the disease.